口服TLR8激动剂Selgantolimod（GS-9688，SLGN）在病毒抑制的成人慢

StephenW

                                                                                                                                                                                                                                                                                              

Efficacy and Safety of 24 Weeks Treatment with Oral TLR8 Agonist Selgantolimod (GS-9688, SLGN) in Virally Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2 Study
	EASL - The Digital International Liver Congress, 27-29 August 2020 Reported by Jules Levin Edward Gane,1 P. Rod Dubar,2 Anna E. Brooks,2 Yang Zhao,3 Susanna K. Tan,3 Audrey H. Lau,3 Jenny C. Yang3, Anuj Gaggar,3  Mani Subramanian,3 Shyam Kottilil,4 Lydia Tang4 1Auckland City Hospital, Auckland, New Zealand; 2School of Biological Sciences, Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand; 3Gilead Sciences, Inc., Foster City, CA, USA;  4Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA